Supernus, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of treatments for patients living with central nervous system (CNS) diseases. Its portfolio includes treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. The company was founded in 2005 and is headquartered in Rockville, MD.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
838
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Supernus Inc. market cap is $5.94B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Supernus Inc. 52 week high is $33.22 as of November 22, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Supernus Inc. 52 week low is $21.48 as of November 22, 2026.
Supernus Inc. stock price today is $28.61.
Supernus Inc. stock price yesterday was $28.35.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Supernus Inc.'s P/E ratio is 7.92.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Supernus Inc. P/B ratio is -56.2668.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Supernus Inc. 50-day moving average is $27.64.